Search clinical trials for: Niacin Extended-Release and simvastatin Tablets

Total 1171 results

Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Kos Pharmaceuticals

Completed

Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)

Hypercholesterolemia
Kos Pharmaceuticals

Completed

Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST

Hypercholesterolemia
Luye Pharma Group Ltd.
Shandong Luye Pharmaceutical Co., Ltd.

Completed

Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH (HDL Proteomics)

Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis

United States, Canada
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)

Coronary Artery Disease | Atherosclerosis | Carotid Artery Diseases

United States, Canada
University of Pennsylvania

Completed

The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study (GENE)

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
Luye Pharma Group Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

China
Organon and Co

Completed

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Hypercholesterolemia
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Johns Hopkins University
Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI); Temple University

Not yet recruiting

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma | Overweight and Obesity | Asthma Chronic
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Migraine Prophylaxis

Bangladesh
Abbott

Recruiting

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia

Malaysia, Armenia
Terran Biosciences Australia Pty Ltd

Recruiting

A Study of Idazoxan in Healthy Participants

Healthy

Australia
Axio Research. LLC
National Heart, Lung, and Blood Institute (NHLBI); Abbott

Terminated

Niacin Plus Statin to Prevent Vascular Events

Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Atherosclerosis | Cerebrovascular Accident

United States, Canada
Methodist Healthcare

Completed

Envarsus XL Immunosuppression Following Liver Transplantation

Recipients of Liver Transplant

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Lewai Sharki Abdulaziz, MSc PhD
Al-Kindy College of Medicine

Completed

Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females

Atherogenic Dyslipidemia | Obesity Associated Disorder

Iraq
Merck Sharp & Dohme LLC

Completed

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED) (MCAT)

Carotid Atherosclerosis
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
Beijing Anzhen Hospital
Novartis

Unknown

Fluvastatin AmelIorates aTHerosclerosis Study (FAITH)

Atherosclerosis | Coronary Heart Disease

China
University of Colorado, Denver

Withdrawn

Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia

Trigeminal Neuralgia
Cortria Corporation
PPD; Pharmena North America

Completed

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Healthy

Canada
Abbott

Completed

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

United States, Canada, Puerto Rico
University of Leipzig

Completed

Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)

Coronary Disease | Hypolipoproteinemia

Germany
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
University of Hawaii
United States Department of Defense

Completed

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

HIV Infections | Dyslipidemia | Endothelial Dysfunction

United States
Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT2)

Diverticulitis

United States, Italy, Germany, Canada, Brazil, Romania, Netherlands, Finland, South Africa, Hungary
George Thanassoulis
Jewish General Hospital; Laval University; Quebec Heart Institute

Withdrawn

Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL)

Aortic Stenosis and Lipoprotein(a) Levels

Canada
North Texas Veterans Healthcare System
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis (ALPINE-SVG)

Aortocoronary Saphenous Vein Bypass Graft Atherosclerosis | Intermediate Saphenous Vein Graft Lesions

United States
Kos Pharmaceuticals

Completed

The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC

Intermittent Claudication | Peripheral Vascular Disease

United States
University of Miami

Terminated

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Diabetes Mellitus, Type 2 | Kidney Failure, Chronic | Hyperlipidemia

United States
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Kos Pharmaceuticals

Completed

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication

Intermittent Claudication | Peripheral Vascular Disease
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition

Fasting

India
Daniel A. Siniawski
Merck Sharp & Dohme LLC

Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Coronary Artery Disease | Dyslipidemias

Argentina
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Brigham and Women's Hospital

Terminated

Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid

Inflammation | Cardiovascular Disease | Atherosclerosis | Dialysis

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia
GlaxoSmithKline

Terminated

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Alzheimer's Disease

United Kingdom
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions

Healthy

United States
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Healthy

United States
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Hannover Medical School

Completed

The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)

Metabolic Syndrome

Germany
Walter Reed Army Medical Center
Abbott

Terminated

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Atherosclerosis

United States

3

Subscribe